|
Treatment preparation
|
IFNβ-1a i.m.
|
IFNβ-1a s.c.
|
IFNβ-1b s.c.
|
|---|
|
Cohort
|
KI Sweden
|
TUM Germany
|
KI Sweden
|
TUM Germany
|
KI Sweden
|
TUM Germany
|
|---|
|
N (%)
|
345 (24.7)
|
251 (18.4)
|
590 (42.3)
|
558 (40.9)
|
459 (32.9)
|
554 (40.6)
|
|
Mean age (SD)
|
46.7 (9.9)
|
40.1 (9.6)
|
44.1 (9.9)
|
38.9 (9.6)
|
45.4 (10.4)
|
41.4 (10.4)
|
|
Female sex (%)
|
216 (62.6)
|
191 (76.1)
|
440 (74.6)
|
406 (72.8)
|
334 (72.8)
|
390 (70.4)
|
|
Median treatment duration in months (MAD)
|
21.0 (8.1)
|
40.0 (20.4)
|
30.0 (15.0)
|
55.2 (23.1)
|
24.9 (12.9)
|
46.9 (23.4)
|
|
Progressive MS (%)
|
60 (17.4)
|
34 (13.5)
|
120 (20.3)
|
90 (16.1)
|
130 (28.3)
|
128 (23.1)
|
|
nADA positive (%)
|
45 (13.0)
|
41 (16.3)
|
204 (34.6)
|
188 (33.7)
|
245 (53.4)
|
255 (46.0)
|
|
Median nADA titer (MAD) nADA-positive samples
|
320 (280)
|
320 (280)
|
640 (600)
|
1280 (1240)
|
320 (280)
|
320 (280)
|
|
Median bADA level (MAD) all samples
|
13.9 (6.5)
|
9.6 (5.7)
|
23.2 (13.9)
|
16.3 (10.5)
|
35.8 (19.9)
|
29.4 (20.0)
|
|
Median bADA level (MAD) nADA-positive samples
|
63.8 (42.6)
|
25.8 (22.3)
|
109.0 (84.8)
|
115.0 (104.0)
|
69.0 (37.0)
|
73.8 (50.7)
|
- N (%) refers to the entire cohort, the other percentages to the respective column. The nADA and bADA measurements shown here were obtained within the present study. Non-parametric summary statistics are provided for variables that were not normally distributed. Progressive MS = patients with a primary or secondary progressive disease course, as opposed to clinically isolated syndrome and relapsing-remitting MS. The dataset contained 1.6% primary progressive, 0.6% progressive-relapsing, and 18.2% secondary progressive MS patients. The frequency of nADA did not differ between progressive (35.2%) and other (35.5%) MS patients. Patients were diagnosed using the current McDonald criteria at the time of diagnosis. KI Karolinska Institutet, Sweden; TUM Technical University of Munich, Germany; SD standard deviation; MAD median absolute deviation
